NR3C1 and precursor B-cell acute lymphoblastic leukemia: These data indicate that idelalisib is a general potentiator of glucocorticoid activity in B-ALL, and the mechanism of idelalisib is to increase the potency of GR in regulating all genes, including cell death effectors, in part by increasing DNA affinity (Figure 4I).